BRD4 Overexpression

CI-VAR-00003170Explore in graph →CIViC 1279

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Childhood Medulloblastoma1
BRD4 Overexpression	JQ1	Predictive	D	Supports Sensitivity Response	2	submitted	EID9316 Predominantly high-level expression of BRD4 was found in the majority of medulloblastoma cell lines examined (HD-MB3, ONS-76, UW-228, D-341, and D-283); the exception being the Daoy cell line exhibiti… (full text at CIViC) PMID 24231268 · Henssen et al., 2013 · Open in CIViC	civic
Clear Cell Renal Cell Carcinoma1
BRD4 Overexpression	JQ1	Predictive	D	Supports Sensitivity Response	2	submitted	EID2957 Renal cell carcinoma (RCC) remains an intractable genitourinary malignancy. Resistance to chemotherapy or targeted therapies in RCC is presumably due to the complicated underlying molecular mechanisms… (full text at CIViC) PMID 28391274 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Melanoma1
BRD4 Overexpression	Unspecified therapy	Predictive	D	Supports Sensitivity Response	3	submitted	EID9315 BET inhibitor JQ-1 induced a decrease in viability to NRAS mutant melanoma cells with an increase in sensitivity in those highly expressing BRD4 in comparison to BRD2 and BRD3 expression (P = 0.018); … (full text at CIViC) PMID 29650805 · Echevarría-Vargas et al., 2018 · Open in CIViC	civic